Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Melanoma × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 513 Carcinoma, Non-Small-Cell Lung 431 Ovarian Neoplasms 285 Lung Neoplasms 179 Neoplasms 136 Fallopian Tube Neoplasms 133 Stomach Neoplasms 117 Esophageal Neoplasms 116 Carcinoma, Ovarian Epithelial 109 Triple Negative Breast Neoplasms 108 Neoplasm Metastasis 105 Squamous Cell Carcinoma of Head and Neck 87 Endometrial Neoplasms 80 Head and Neck Neoplasms 73 Esophageal Squamous Cell Carcinoma 67 Uterine Cervical Neoplasms 64 Recurrence 45 Adenocarcinoma of Lung 42 Urinary Bladder Neoplasms 39 Parkinson Disease 4, Autosomal Dominant Lewy Body 39 Carcinoma 38 Melanoma 35 Adenocarcinoma Of Esophagus 34 Prostatic Neoplasms 33 Carcinoma, Squamous Cell 32 Pancreatic Neoplasms 29 Small Cell Lung Carcinoma 28 Unspecified Adult Solid Tumor, Protocol Specific 26 Breast Neoplasms, Male 26 Colorectal Neoplasms 24

Interventions

pembrolizumab 1 Temozolomide 1 Paclitaxel 1 Dacarbazine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07310784 2026-03-03

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡